HANSHOW
7.6.2024 10:31:31 CEST | Business Wire | Press release
Hanshow, a leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Leroy Merlin, a global DIY leader, have partnered to enhance customer and employee experiences by deploying ESLs across over 50,000 products integrated with the Leroy Merlin mobile app in France. Customers now enjoy seamless shopping with easy product geolocation and personalized recommendations in Leroy Merlin stores. After 18 months of R&D, they implemented a fully customized solution in all Leroy Merlin outlets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604438443/en/
Hanshow's ESL Solution at Leroy Merlin. (Graphic: Business Wire)
Enhanced Customer Support with Leroy Merlin's Mobile Application
This immersive experience is powered by the Leroy Merlin mobile application in conjunction with Hanshow's state-of-the-art ESL solutions. Leroy Merlin’s integration of Hanshow ESL into its app offers geolocation in-store to guide customers to products and aisles. This enhances the shopping experience and allows staff to provide more personalized advice and support.
The ESL solution also provides price consistency between online and offline channels, enriching user experience with various features such as customer reviews, enriched product descriptions, access the Home Index to assess a product's environmental and social impact, and the ability to flash labels directly from the application. These functions provide flexibility for consumers and store associates.
"We have successfully met the expectations of Leroy Merlin customers by developing a solution that enhances the in-store experience. By combining data and technological innovations, we have created a tailor-made tool that delivers a personalized experience for each customer," explains Pierre Fosseux, VP of Hanshow France.
Enhancing Retail Efficiency and Customer Experience
Whether it's stock management, restocking, or click-and-collect order preparation, the geolocation of products in the shop is a real time-saver for staff, who can devote themselves to focusing on higher-value tasks. "It now takes sales staff around 75 seconds to pick up a product, instead of 90 seconds previously, for orders placed online and picked up in the shop within a two-hour window chosen by the customer," says Olivier Personne, Merchandising Optimization Manager at Leroy Merlin. Eliminating price differences has positively improved customer satisfaction.
"The solution co-constructed with Hanshow enriches the customer experience across online and offline channels while simplifying in-store team tasks. Currently deployed in France, it is designed for larger-scale rollout in other Leroy Merlin locations," explains Hugues Hartung de la Roer, Concept & Merchandising Director at Leroy Merlin France.
Exemplifying both companies' commitment to enhancing customer satisfaction and driving innovation in the retail sector, the new solution not only simplifies the shopping process but also provides valuable data insights to improve store operations and customer engagement.
The collaboration won the Reta Awards 2024: Best In-store Solution for Leroy Merlin and Top Supplier for Hanshow, for transforming the retail environment with advanced technology.
About Leroy Merlin France
A pioneering company in the Adeo Group, Leroy Merlin is now the leading brand in France in all distribution channels for improving the home and the living environment. Specialising in the sale of products, projects and services, Leroy Merlin France has set itself the goal of building new ways of living with everyone, so that we can live better in the future, and puts customer satisfaction at the heart of its business.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions . The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604438443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom